ANKRD55

Summary

ANKRD55 (ankyrin repeat domain 55, HGNC:25681) is a protein-coding gene on chromosome 5q11.2, encoding Ankyrin repeat domain-containing protein 55 (Q3KP44).

At a glance

• GWAS associations: 79
• Clinical variants (ClinVar): 107 total — 1 pathogenic
• Phenotypes (HPO): 45
• MANE Select transcript: NM_024669

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25681
Approved symbol	ANKRD55
Name	ankyrin repeat domain 55
Location	5q11.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11795
Ensembl gene	ENSG00000164512
Ensembl biotype	protein_coding
OMIM	615189
Entrez	79722

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000341048, ENST00000434982, ENST00000504958, ENST00000505970, ENST00000513241, ENST00000519114

RefSeq mRNA: 1 — MANE Select: NM_024669 NM_024669

CCDS: CCDS34161

Canonical transcript exons

ENST00000341048 — 12 exons

Exon	Start	End
ENSE00001378414	56170694	56170803
ENSE00001379127	56126922	56127106
ENSE00001383872	56176152	56176282
ENSE00001408116	56233241	56233330
ENSE00001415049	56099680	56100304
ENSE00002090182	56111118	56111782
ENSE00002139579	56102494	56102586
ENSE00003509067	56183512	56183634
ENSE00003562023	56159833	56159893
ENSE00003629033	56232856	56232946
ENSE00003678119	56116615	56116782
ENSE00003683539	56143801	56143929

Expression profiles

Bgee: expression breadth ubiquitous, 169 present calls, max score 85.26.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4319 / max 111.4469, expressed in 279 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
61733	0.5999	86
61730	0.4151	102
61734	0.2773	83
61731	0.0906	46
61729	0.0431	24
61735	0.0058	2

Top tissues by expression

273 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.26	gold quality
sperm	CL:0000019	84.22	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.21	gold quality
male germ cell	CL:0000015	82.06	gold quality
blood	UBERON:0000178	77.80	gold quality
lymph node	UBERON:0000029	72.77	gold quality
leukocyte	CL:0000738	71.44	gold quality
monocyte	CL:0000576	71.25	gold quality
mononuclear cell	CL:0000842	71.20	gold quality
granulocyte	CL:0000094	70.50	gold quality
prefrontal cortex	UBERON:0000451	68.09	gold quality
hypothalamus	UBERON:0001898	67.83	gold quality
buccal mucosa cell	CL:0002336	67.32	gold quality
testis	UBERON:0000473	66.13	gold quality
left testis	UBERON:0004533	65.76	gold quality
right testis	UBERON:0004534	65.63	gold quality
nucleus accumbens	UBERON:0001882	65.58	gold quality
anterior cingulate cortex	UBERON:0009835	63.40	gold quality
cingulate cortex	UBERON:0003027	63.37	gold quality
spleen	UBERON:0002106	62.70	gold quality
adult organism	UBERON:0007023	62.65	gold quality
frontal cortex	UBERON:0001870	62.61	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	61.92	gold quality
bone marrow	UBERON:0002371	61.85	gold quality
trabecular bone tissue	UBERON:0002483	61.85	silver quality
neocortex	UBERON:0001950	61.67	gold quality
right lobe of liver	UBERON:0001114	61.62	gold quality
liver	UBERON:0002107	61.52	gold quality
amygdala	UBERON:0001876	60.73	gold quality
right frontal lobe	UBERON:0002810	60.73	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.24
E-MTAB-7249	no	2.94

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

54 targeting ANKRD55, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-373-3P	99.84	70.68	1668
HSA-MIR-520E-3P	99.84	70.55	1698
HSA-MIR-520B-3P	99.83	70.56	1699
HSA-MIR-520C-3P	99.83	70.56	1699
HSA-MIR-372-3P	99.83	70.58	1691
HSA-MIR-520A-3P	99.83	70.59	1687
HSA-MIR-520D-3P	99.83	70.78	1676
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-6885-3P	99.75	70.36	3187

Literature-anchored findings (GeneRIF, showing 9)

• ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. (PMID:22130326)
• Performed a genome-wide significant association study of ANKRD55 rs6859219 and multiple sclerosis risk. Genotyped ANKRD55 rs6859219 in 5106 MS cases and 3740 healthy control subjects. (PMID:23315543)
• ANKRD55 rs459193 and GRB14 rs13389219 associate with insulin resistance. (PMID:23457408)
• The present study was conducted to shed light on the expression of ANKRD55 in the immune and nervous systems, to investigate the possible relationship of rs6859219 with ANKRD55 expression regulation, and to explore the relationship of ANKRD55 with Multiple Sclerosis. (PMID:27183579)
• This is the first study to demonstrate a positive association between ANKRD55 polymorphism and dermatomyositis/polymyositis with interstitial lung disease (DM/PM)-ILD . A decreased frequency of rs7731626-A in DM-ILD and DM/PM-ILD patients suggests that the A variant may be protective against DM/PM-ILD. (PMID:28470010)
• Interactome of the Autoimmune Risk Protein ANKRD55. (PMID:31620119)
• Investigating the association of polymorphisms of ANKRD55 and MMEL1 with susceptibility to multiple sclerosis in Iranian population. (PMID:33491520)
• Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. (PMID:33536079)
• Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55-IL6ST Gene Region in Immature Dendritic Cells. (PMID:35111166)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ankrd55	ENSDARG00000099182
mus_musculus	Ankrd55	ENSMUSG00000049985
rattus_norvegicus	Ankrd55	ENSRNOG00000013555

Paralogs (3): ANKRD44 (ENSG00000065413), ANKRD52 (ENSG00000139645), ANKRD28 (ENSG00000206560)

Protein

Protein identifiers

Ankyrin repeat domain-containing protein 55 — Q3KP44 (reviewed: Q3KP44)

All UniProt accessions (3): Q3KP44, D6R9N4, D6RBD3

Isoforms (3)

UniProt ID	Names	Canonical?
Q3KP44-1	1	yes
Q3KP44-2	2
Q3KP44-3	3

RefSeq proteins (1): NP_078945* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily

Pfam: PF00023, PF12796

UniProt features (22 total): repeat 9, region of interest 5, compositionally biased region 2, splice variant 2, sequence variant 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q3KP44-F1	63.43	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 475

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 203 (showing top): LEE_EARLY_T_LYMPHOCYTE_DN, LEIN_MIDBRAIN_MARKERS, LEIN_PONS_MARKERS, LEIN_MEDULLA_MARKERS, chr5q11, ZHENG_BOUND_BY_FOXP3, LEE_RECENT_THYMIC_EMIGRANT, AR_Q6, HUTTMANN_B_CLL_POOR_SURVIVAL_UP, RAO_BOUND_BY_SALL4_ISOFORM_B, IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP, GSE14699_NAIVE_VS_ACT_CD8_TCELL_DN, GSE13946_CTRL_VS_DSS_COLITIS_GD_TCELL_FROM_COLON_DN, GSE14415_FOXP3_KO_NATURAL_TREG_VS_TCONV_DN, GSE14415_NATURAL_TREG_VS_TCONV_UP

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

1410 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANKRD55	ZNF626	Q68DY1	593
ANKRD55	GRB14	Q14449	584
ANKRD55	ARL15	Q9NXU5	581
ANKRD55	PRTFDC1	Q9NRG1	570
ANKRD55	MACIR	Q96GV9	548
ANKRD55	LYPLAL1	Q5VWZ2	517
ANKRD55	DENND4A	Q7Z401	487
ANKRD55	AFF3	P51826	480
ANKRD55	CCDC138	Q96M89	477
ANKRD55	KLHL42	Q9P2K6	477
ANKRD55	PTPN22	Q9Y2R2	475
ANKRD55	ANTXR2	P58335	463
ANKRD55	LRATD1	Q96KN4	455
ANKRD55	PEPD	P12955	454
ANKRD55	CLHC1	Q8NHS4	454

IntAct

71 interactions, top by confidence:

A	B	Type	Score
CIAO1	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
FANCL	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	FHL5	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	FANCL	psi-mi:“MI:0915”(physical association)	0.560
HSF2BP	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	BACH2	psi-mi:“MI:0915”(physical association)	0.560
NCK2	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	PFDN5	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	ABI2	psi-mi:“MI:0915”(physical association)	0.560
HGS	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	NOXA1	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	CABP5	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	ZMYND19	psi-mi:“MI:0915”(physical association)	0.560
CLIC3	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	TEKT4	psi-mi:“MI:0915”(physical association)	0.560
FHL2	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
FRS3	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	BANP	psi-mi:“MI:0915”(physical association)	0.560
BOLA2-SMG1P6	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
PTK6	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	CFAP206	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	ANKS1A	psi-mi:“MI:0915”(physical association)	0.560
TRIM23	ANKRD55	psi-mi:“MI:0915”(physical association)	0.560
ANKRD55	ZSCAN1	psi-mi:“MI:0915”(physical association)	0.370
ANKRD55	PTCHD1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (260): IFT46 (Affinity Capture-MS), TTC30B (Affinity Capture-MS), TTC30A (Affinity Capture-MS), IFT74 (Affinity Capture-MS), IFT52 (Affinity Capture-MS), HIF1AN (Affinity Capture-MS), TRIP6 (Affinity Capture-MS), TTC30A (Affinity Capture-MS), IFT52 (Affinity Capture-MS), IFT46 (Affinity Capture-MS), IFT74 (Affinity Capture-MS), TTC30B (Affinity Capture-MS), HIF1AN (Affinity Capture-MS), MIB1 (Affinity Capture-MS), YWHAG (Affinity Capture-MS)

ESM2 similar proteins: A2RRS8, A5PLL1, A6H694, B6D5P1, B6D5P3, B8A5Y1, F1MCA7, P0C6C1, P62046, P70587, Q05C16, Q06190, Q08AD1, Q3KP44, Q3KQW7, Q3U3V8, Q3UMB5, Q3UMG5, Q3UUF8, Q5DTV4, Q5PQ89, Q5RJ80, Q5SW75, Q5VUJ6, Q6GPJ8, Q6IE24, Q6IRU7, Q6P2D8, Q70EL1, Q76I76, Q80TE7, Q80TH2, Q8BL06, Q8BLB8, Q8BLD6, Q8BVU0, Q8C115, Q8IVE3, Q8K4P8, Q8TEV9

Diamond homologs: A2ARS0, B2RXR6, C7B178, C9JTQ0, P0C927, P19838, Q00PJ3, Q07E43, Q08353, Q21920, Q29RM5, Q2QL84, Q337A0, Q3KP44, Q3SX00, Q3UES3, Q3UUF8, Q4FE45, Q4JHE0, Q4V890, Q502K3, Q5R8C8, Q5ZLC8, Q60J38, Q6KAE5, Q6TNT2, Q76K24, Q7EZ44, Q86W74, Q86WC6, Q8BTI7, Q8BTZ5, Q8C0T1, Q8NB46, Q8VHS5, Q9BSK4, Q9D119, Q9H2K2, Q9N3Q8, Q9Z2G1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	86
Likely benign	6
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2424366	NC_000005.9:g.(?52285299)(56189507_?)del	Pathogenic

SpliceAI

2486 predictions. Top by Δscore:

Variant	Effect	Δscore
5:56100300:TAGAA:T	acceptor_gain	1.0000
5:56100301:AGAA:A	acceptor_gain	1.0000
5:56100302:GAA:G	acceptor_gain	1.0000
5:56100303:AA:A	acceptor_gain	1.0000
5:56100304:AC:A	acceptor_loss	1.0000
5:56100305:C:CA	acceptor_loss	1.0000
5:56100305:C:CC	acceptor_gain	1.0000
5:56100306:T:G	acceptor_loss	1.0000
5:56116610:CTCA:C	donor_loss	1.0000
5:56116611:TCA:T	donor_loss	1.0000
5:56116612:CACCT:C	donor_loss	1.0000
5:56116613:A:AC	donor_gain	1.0000
5:56116613:A:T	donor_loss	1.0000
5:56116614:C:CC	donor_gain	1.0000
5:56116614:C:T	donor_loss	1.0000
5:56116614:CCTG:C	donor_gain	1.0000
5:56116792:CCA:C	acceptor_gain	1.0000
5:56116793:CA:C	acceptor_gain	1.0000
5:56116794:A:AC	acceptor_gain	1.0000
5:56116794:A:C	acceptor_gain	1.0000
5:56116796:G:C	acceptor_gain	1.0000
5:56143795:TCTCA:T	donor_loss	1.0000
5:56143796:CTCAC:C	donor_loss	1.0000
5:56143797:TCA:T	donor_loss	1.0000
5:56143798:CA:C	donor_loss	1.0000
5:56143799:ACCTG:A	donor_loss	1.0000
5:56143800:C:CA	donor_loss	1.0000
5:56159827:GCTCA:G	donor_loss	1.0000
5:56159828:CTCA:C	donor_loss	1.0000
5:56159830:CA:C	donor_loss	1.0000

AlphaMissense

4064 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:56170778:A:G	L113P	0.998
5:56176173:A:C	S97R	0.998
5:56176173:A:T	S97R	0.998
5:56176175:T:G	S97R	0.998
5:56176180:C:G	R95P	0.998
5:56176225:A:G	L80P	0.998
5:56176258:A:T	V69D	0.998
5:56176262:C:G	A68P	0.998
5:56183589:G:T	A35D	0.998
5:56176193:C:G	D91H	0.997
5:56176225:A:T	L80Q	0.997
5:56176228:A:G	L79P	0.997
5:56176273:G:T	P64H	0.997
5:56159841:C:G	D159H	0.996
5:56170727:G:C	P130R	0.996
5:56170775:A:G	L114P	0.996
5:56176192:T:A	D91V	0.996
5:56176225:A:C	L80R	0.996
5:56176261:G:T	A68E	0.996
5:56176273:G:C	P64R	0.996
5:56183565:A:G	L43P	0.996
5:56183580:C:A	G38V	0.996
5:56143868:A:G	L182P	0.995
5:56143908:C:G	A169P	0.995
5:56170778:A:T	L113Q	0.995
5:56176162:G:T	A101D	0.995
5:56176270:A:C	L65W	0.995
5:56176270:A:G	L65S	0.995
5:56183553:A:T	I47N	0.995
5:56143871:A:G	L181P	0.994

dbSNP variants (sampled 300 via entrez): RS1000000685 (5:56211743 G>C), RS1000044004 (5:56107760 C>T), RS1000051899 (5:56139280 C>T), RS1000062845 (5:56146284 C>A), RS1000063585 (5:56150832 G>A), RS1000077814 (5:56126033 T>C), RS1000096644 (5:56146543 A>C,T), RS1000129965 (5:56126203 A>G), RS1000145188 (5:56224729 C>A), RS1000153360 (5:56106652 G>A), RS1000158786 (5:56168472 T>C,G), RS1000162468 (5:56103934 T>C), RS1000212961 (5:56104265 C>T), RS1000223461 (5:56129057 A>G), RS1000237650 (5:56123195 G>A)

Disease associations

OMIM: gene MIM:615189 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

45 total (30 of 45 shown, HPO-id order):

HPO	Term
HP:0000501	Glaucoma
HP:0000518	Cataract
HP:0000554	Uveitis
HP:0000572	Visual loss
HP:0000585	Band keratopathy
HP:0001094	Iridocyclitis
HP:0001155	Abnormality of the hand
HP:0001369	Arthritis
HP:0001370	Rheumatoid arthritis
HP:0001371	Flexion contracture
HP:0001382	Joint hypermobility
HP:0001384	Abnormal hip joint morphology
HP:0001386	Joint swelling
HP:0001387	Joint stiffness
HP:0001433	Hepatosplenomegaly
HP:0001508	Failure to thrive
HP:0001530	Mild postnatal growth retardation
HP:0001785	Ankle swelling
HP:0001824	Weight loss
HP:0001832	Abnormal metatarsal morphology
HP:0001903	Anemia
HP:0002716	Lymphadenopathy
HP:0002829	Arthralgia
HP:0002960	Autoimmunity
HP:0003019	Abnormality of the wrist
HP:0003028	Abnormality of the ankle
HP:0003043	Abnormal shoulder morphology
HP:0003319	Abnormality of the cervical spine
HP:0003326	Myalgia
HP:0003493	Antinuclear antibody positivity

GWAS associations

79 associations (top):

Study	Trait	p-value
GCST000758_30	Triglycerides	1.000000e-10
GCST000987_2	Celiac disease or Rheumatoid arthritis	3.000000e-07
GCST001791_22	Urate levels	3.000000e-06
GCST001848_128	IgG glycosylation	2.000000e-06
GCST001848_135	IgG glycosylation	2.000000e-06
GCST001848_246	IgG glycosylation	3.000000e-10
GCST001848_34	IgG glycosylation	1.000000e-10
GCST001848_354	IgG glycosylation	4.000000e-06
GCST001848_43	IgG glycosylation	1.000000e-10
GCST001848_491	IgG glycosylation	1.000000e-10
GCST001848_50	IgG glycosylation	8.000000e-06
GCST001848_529	IgG glycosylation	7.000000e-11
GCST001848_650	IgG glycosylation	2.000000e-07
GCST001848_93	IgG glycosylation	2.000000e-09
GCST001915_8	Alzheimer’s disease (cognitive decline)	1.000000e-08
GCST002318_132	Rheumatoid arthritis	8.000000e-23
GCST002318_42	Rheumatoid arthritis	7.000000e-24
GCST002782_134	Waist-to-hip ratio adjusted for body mass index	2.000000e-11
GCST002782_135	Waist-to-hip ratio adjusted for body mass index	5.000000e-09
GCST002782_136	Waist-to-hip ratio adjusted for body mass index	5.000000e-12
GCST002782_34	Waist-to-hip ratio adjusted for body mass index	7.000000e-09
GCST003097_12	Pediatric autoimmune diseases	1.000000e-10
GCST003400_36	Type 2 diabetes	1.000000e-10
GCST003495_1	Post-traumatic stress disorder	6.000000e-08
GCST003566_11	Multiple sclerosis	8.000000e-09
GCST003619_10	Type 2 diabetes	3.000000e-09
GCST004132_99	Crohn’s disease	5.000000e-06
GCST004505_13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	9.000000e-13
GCST004505_14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	2.000000e-13
GCST004507_38	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)	2.000000e-09

EFO canonical traits (14, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004531	urate measurement
EFO:0005193	serum IgG glycosylation measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0004318	smoking behavior
EFO:0008002	physical activity measurement
EFO:0005091	monocyte count
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004314	forced expiratory volume
EFO:0006939	cup-to-disc ratio measurement
EFO:0007986	reticulocyte count
EFO:0007989	monocyte percentage of leukocytes
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs160919	ANKRD55		0.00	0

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, increases methylation	1
butyraldehyde	increases expression	1
pentanal	increases expression	1
entinostat	increases expression	1
Poly(amidoamine)	increases expression	1
bisphenol S	decreases methylation	1
(+)-JQ1 compound	decreases expression	1
Venlafaxine Hydrochloride	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Aldehydes	increases expression	1
Arsenic	affects methylation	1
Vehicle Emissions	decreases methylation	1
Benzo(a)pyrene	affects methylation	1
Estradiol	affects cotreatment, increases expression	1
Malathion	increases expression	1
Progesterone	affects cotreatment, increases expression	1
Silicon Dioxide	increases expression	1
Urethane	decreases expression	1
Valproic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.